CBR1

Across TCGA pan-cancer cohorts, CBR1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CBR1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CBR1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CBR1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CBR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.649	0.439	<.001	114	view →
GBM	OS	Median	All	0.433	0.624	.008	11	view →
CCRCC	DFS	Median	II,III,IV	0.584	0.832	.017	8	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	6	view →
HNSC	DFS	Quartile	III,IV	0.961	0.644	.017	4	view →
LSCC	DFS	Quartile	All	0.571	1.000	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CBR1–PDAC (OS)

Open the PDAC breakdown →